Stockscreener 앱 받기
1.19
11.85%
-0.16
시간 외 거래:
1.26
0.07
+5.88%
Jaguar Health Inc 주식(JAGX)의 최신 뉴스
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Central New Jersey News
Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada
Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus
Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com
Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Sarasota Herald-Tribune
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union
FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia
FDA extends conditional approval for Jaguar Health’s canine drug - Investing.com
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Daytona Beach News-Journal
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today
Jaguar Health announces promising trial results for crofelemer - MSN
Jaguar Health Announces Promising Trial Results for Crofelemer - TipRanks
Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Livingston Daily
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - Daily Commercial
Sakthi Sugars Limited (SAKHTISUG) vs yyyFibonacci Extensions & Free Gain Edge With Data - earlytimes.in
0.36%
1.05%
자본화:
|
볼륨(24시간):